BDNF and psychiatric disorder: The secondary outcomes of interest are patient functioning (measured using the Strauss and Carpenter Prognostic Scale, Global Assessment of Functioning (GAF) scale, Functioning Assessment Short Test (FAST)), adherence (Morisky Green Medication Adherence Scale), insight (Scale to Assess Unawareness of Mental Disorders (SUMD)), social response (Liebowitz Social Anxiety Scale (LSAS)), quality of life (World Health Organization Quality of Life instrument WHOQOL-BREF (an abbreviated version of the WHOQOL-100) and the EuroQoL questionnaire), and brain-derived neurotrophic factor (BDNF) level.